Med24
overweight-obesity 29. 9. 2026 • 2 min read • Women's health nursing (Seoul, Korea)

Clinical evaluation and treatment of obesity in women across selected life stages: a narrative review

Purpose This study was performed to synthesize current evidence on evaluating and treating obesity in women across selected life stages relevant to women's health nursing practice. Methods For this invited narrative review, targeted searches of PubMed and guideline and regulatory sources available through July 2026...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

This study synthesized evidence regarding the evaluation and treatment of obesity in women across various life stages, relevant to women’s health nursing. The review examined diagnostic frameworks, including The Lancet criteria for clinical obesity and the Edmonton Obesity Staging System, alongside assessments incorporating mechanical, metabolic, mental, and social factors. These approaches complement body mass index in confirming adiposity, diagnosing illness, and staging severity. The research also considered Korean and international guidance, pharmacotherapy evidence, and literature on reproductive and menopausal physiology.

Medication selection should be based on approved indications, efficacy, safety, comorbidities, reproductive plans, access, and patient preferences. Phenotype-guided matching remains an area of ongoing investigation. Care for women of reproductive age requires addressing polycystic ovary syndrome, pregnancy intention, and specific precautions related to tirzepatide. During pregnancy and lactation, individual weight trajectories and medication safety are prioritized over pharmacologic weight loss.

Declining estradiol during the menopausal transition is linked to central fat redistribution, alongside lean mass loss associated with aging. The independent effect of follicle-stimulating hormone has not been established. Menopausal hormone therapy should be prescribed for established menopausal indications, not solely for weight loss.

Sponsored content

Obesity care for women should integrate disease-based assessment, individualized treatment, medication counseling tailored to life stage, nonstigmatizing communication, and shared decision-making. Nurses should support assessment, education, monitoring, and coordination within their professional scope.

Original Scientific Source
Women's health nursing (Seoul, Korea)
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study
overweight-obesity

Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study

Summary Background Hand and shoulder soft-tissue disorders cluster in people with obesity and diabetes, now widely treated with incretin receptor agonists. Whether these disorders share genetic causes, and whether pharmacological weight loss relieves or provokes them, is unknown. Methods We analysed genome-wide data...

28. 10. 2026 Read article →
The interpretation of body-composition metrics in obesity
overweight-obesity

The interpretation of body-composition metrics in obesity

Modern obesity care is increasingly therapeutic, longitudinal, and outcome-oriented, yet clinical assessment often remains centered on total body weight and BMI. Although BMI remains useful for screening and population-level risk stratification, it cannot characterize the biological heterogeneity of obesity or the...

26. 10. 2026 Read article →
Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m 2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial
overweight-obesity

Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m 2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial

Background Orforglipron, an oral small-molecule glucagon-like peptide-1 receptor agonist, improved body weight and cardiometabolic parameters in the phase 3 ATTAIN-1 trial, but its efficacy and safety in adults with body mass index (BMI) of ≥27 to 2 and adiposity-related complications have not been characterized....

14. 10. 2026 Read article →
Advertisement